hydralazine has been researched along with aliskiren in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 9 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Dong, YF; Fukuda, M; Kataoka, K; Kim-Mitsuyama, S; Liu, L; Nakamura, T; Nako, H; Ogawa, H; Tokutomi, Y | 1 |
| Ayuzawa, N; Fujita, T; Ishizawa, K; Kawarazaki, W; Nagase, M; Takeuchi, M; Ueda, K; Yoshida, S | 1 |
| Cheng, XW; Hamrah, MS; Hao, CN; Hayashi, M; Hu, L; Kuzuya, M; Murohara, T; Shi, GP; Takeshita, K; Wu, H | 1 |
| Chang, TT; Chen, JS; Chen, JW; Huang, PH; Lin, CP; Lin, LY; Lin, SJ; Wu, TC | 1 |
| Chang, TT; Chen, JS; Chen, JW; Huang, PH; Lin, LY; Lin, SJ; Wu, TC | 1 |
| Adhikari, S; Alpert, L; Bissonnette, M; Chen, L; Deb, DK; Dougherty, U; Hart, J; He, L; Kwon, J; Li, YC; Liu, SQ; Liu, T; Liu, W; Pekow, J; Rubin, DT; Shi, Y; Wang, J; Zhao, Q; Zhou, G | 1 |
| Adhyaru, B; Raj, L | 1 |
| Asselin, CY; Cheung, D; Czaykowski, P; Dingman, B; Edel, A; Goyal, V; Jassal, DS; Kim, E; Mittal, I; Mozolevska, V; Ravandi, A; Schwartz, A; Shaikh, B; Singal, PK; Thliveris, J | 1 |
2 review(s) available for hydralazine and aliskiren
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
An evidence-based review of recent advances in therapy for heart failure with reduced ejection fraction (HFrEF).
Topics: Adrenergic beta-Antagonists; American Heart Association; Amides; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anticoagulants; Antihypertensive Agents; Atrial Natriuretic Factor; Benzazepines; Biphenyl Compounds; Calcium Channel Blockers; Cardiology; Cardiotonic Agents; Cardiovascular Agents; Digoxin; Diuretics; Drug Combinations; Erythropoietin; Evidence-Based Medicine; Fumarates; Heart Failure; Hematinics; Humans; Hydralazine; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Iron; Isosorbide Dinitrate; Ivabradine; Mineralocorticoid Receptor Antagonists; Peptide Fragments; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Societies, Medical; Stroke Volume; Tetrazoles; United States; Valsartan; Vasodilator Agents | 2016 |
7 other study(ies) available for hydralazine and aliskiren
| Article | Year |
|---|---|
Aliskiren prevents cardiovascular complications and pancreatic injury in a mouse model of obesity and type 2 diabetes.
Topics: Amides; Animals; Antihypertensive Agents; Blood Pressure; Body Weight; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Fumarates; Glucose Intolerance; Hydralazine; Mice; Mice, Inbred C57BL; Mice, Inbred Strains; Obesity; Organ Size; Pancreas; Renin | 2010 |
Renin inhibition ameliorates renal damage through prominent suppression of both angiotensin I and II in human renin angiotensinogen transgenic mice with high salt loading.
Topics: Albuminuria; Amides; Angiotensin I; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Angiotensinogen; Animals; Antihypertensive Agents; Blood Pressure; Cytoprotection; Disease Models, Animal; Disease Progression; Down-Regulation; Fumarates; Humans; Hydralazine; Hypertension; Kidney; Kidney Diseases; Mice; Mice, Transgenic; Ramipril; Renin; Renin-Angiotensin System; Sodium Chloride, Dietary; Time Factors | 2014 |
Renin inhibition reduces atherosclerotic plaque neovessel formation and regresses advanced atherosclerotic plaques.
Topics: Amides; Angiotensin II; Animals; Aorta; Apolipoproteins E; Atherosclerosis; Blood Pressure; Carrier Proteins; Cathepsins; Chemokine CCL2; Extracellular Matrix; Fumarates; Gene Silencing; Human Umbilical Vein Endothelial Cells; Humans; Hydralazine; Immunohistochemistry; Intracellular Signaling Peptides and Proteins; Macrophages; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Neovascularization, Pathologic; Nuclear Proteins; Plaque, Atherosclerotic; Receptor, Angiotensin, Type 1; Renin; Toll-Like Receptor 2; Treatment Outcome; Vascular Cell Adhesion Molecule-1 | 2014 |
Direct Renin Inhibition with Aliskiren Improves Ischemia-Induced Neovasculogenesis in Diabetic Animals via the SDF-1 Related Mechanism.
Topics: Amides; Animals; Antibodies, Monoclonal; Blood Pressure; Chemokine CXCL12; Diabetes Mellitus, Experimental; Endothelial Progenitor Cells; Fumarates; Humans; Hydralazine; Ischemia; Mice; Neovascularization, Physiologic; Renin; Vascular Endothelial Growth Factor A | 2015 |
Aliskiren directly improves endothelial progenitor cell function from Type II diabetic patients.
Topics: Amides; Antihypertensive Agents; Blotting, Western; Cell Adhesion; Cell Movement; Cell Proliferation; Cells, Cultured; Chemokine CXCL12; Diabetes Mellitus, Type 2; Endothelial Progenitor Cells; Fumarates; Humans; Hydralazine; Imidazoles; In Vitro Techniques; Nitric Oxide Synthase Type III; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Tetrazoles; Vascular Endothelial Growth Factor A | 2016 |
Activation of the Renin-Angiotensin System Promotes Colitis Development.
Topics: Amides; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Apoptosis; Colitis; Colon; Epithelial Cells; Fumarates; Humans; Hydralazine; Inflammatory Bowel Diseases; Losartan; Mice; Mice, Transgenic; Receptor, Angiotensin, Type 1; Renin; Renin-Angiotensin System; Th17 Cells | 2016 |
Role of renin-angiotensin system antagonists in the prevention of bevacizumab- and sunitinib-mediated cardiac dysfunction.
Topics: Amides; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Antineoplastic Agents; Bevacizumab; Cardiotoxicity; Fumarates; Hydralazine; Male; Mice; Mice, Inbred C57BL; Perindopril; Renin-Angiotensin System; Sunitinib; Valsartan; Ventricular Dysfunction | 2019 |